INTERVENTIONS TO FACILITATE MBS IN NON-AMBULANT PATIENTS

CHRISTINE STIER UNIVERSITY MEDICINE MANNHEIM, GERMANY

XXVII IFSO World Congress



CONFLICT OF INTEREST DISCLOSURE

In accordance with «EACCME criteria for the Accreditation of Live Educational Events», please disclose whether you have or not any conflict of interest with the companies:


I have the following potential conflict(s) of interest to report:

Receipt of honoraria or consultation fees

- USGI
- Boston Scientific
- NovoNordisc
- Cranax Medical Digestive
- Johnson & Johnson USA/Europe
- Lohmann & Rauscher
- Morphic Medical
- Trans.Duodenal.Concepts

XXVII IFSO World Congress





Original article

Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity – A proof of concept study

Christine Stier ^{a, b, c, d, *}, Ann-Cathrin Koschker ^d, Mia Kim ^{e, f}, Raphael Stier ^g, Sonja Chiappetta ^h, Jürgen Stein ⁱ

XXVII IFSO World Congress




Internal Rating Scale: Necessity of immediate hospitalization with fast-track rescue weight reduction bridging therapy to obesity surgery is indicated from a total of 14 points upwards or a full score for physical or pulmonary status.

Individual status	Age	>40	1						
		>50	2						
	Gender	Female	0			0			
		Male	2	Pulmonary status	Not breathless with physical activity				
	BMI	Obesity class III > 40 kg/m ²	2		(two flights of stairs)				
		Obesity class III > 50 kg/m ²	3		Breathless with physical activity (two	2			
		Obesity class III > 60 kg/m ²	4		flights of stairs)				
		Obesity class III > 65 kg/m ²	5		Confirmed sleep apnea	3			
		Obesity class III $> 70 \text{ kg/m}^2$	6		Obesity hypoventilation syndrome				
		Obesity class III > 75 kg/m ²	8		Permanently dependent on oxygen				
Functional status		Independent	0		supply				
		Partially dependent	2		Tracheotomy	8			
		Totally dependent	4	Type 2 diabetes status	Oral antidiabetic drug(s): HbA1c < 7.5%	1			
		Wheelchair-dependent	6	21	Insulin-dependent: HbA1c $< 7.5\%$	2			
		Immobile	8		Oral antidiabetic drug(s): HbA1c 7.5%				
Physical status (mo	odified	Normally healthy patient (according to	0		-10%				
according to ASA	A	ASA 1)			Insulin-dependent: HbA1c 7.5%–10%	6			
classification)		Mild systemic disease (according to ASA	2		HbA1c > 10%	8			
		2)							
		Severe systemic disease (according to	4		on system of the American Society of Anesthe	esiolo-			
		ASA 3) including hypertension,		gists (ASA); NAFLD, non-alcoholic fatty liver disease.					
		dyslipidemia (well controlled under							
		medication) and NAFLD							
		Severe systemic disease with threat to	6						
		life (according to ASA 4) including							
		uncontrolled hypertension,							
		dyslipidemia and NAFLD with severe							
		hepatomegaly							
		Severe systemic disease with threat to	8						
		life and urgent need for weight loss	-						
		surgery (ultima ratio) to improve							
		physical condition (according to ASA 5)							
		physical condition (according to ASA 5)							

XXVII IFSO World Congress



Propensity score matched groups: Intragastric Balloon versus medical treatment (GLP-1 + AA-infusion)



XXVII IFSO World Congress



Baseline patient data

27P (IGB) 14fm/13m	Mean	SD	Min	Мах	20P (MCT) 14fm/13m	Mean	SD	Min	Мах	
Age years	40,48	6,43	29	54	Age years	42,7	9,50	29	54	n.s.
Height cm	171,37	9,82	155	187	Height cm	175	11,39	157	198	n.s.
Basic BMI kg/m²	77,47	8,34	61,3	95,7	Basic BMI kg/m²	73,29	8,72	60,2	94,6	n.s.
Basic Weight kg	226,77	33,96	157	305	Basic Weight kg	229,55	38,30	166	338	n.s.
Excess weight kg	156,18	28,08	97	225	Excess weight kg	155,4	33,13	152	280	n.s.

XXVII IFSO World Congress




Intragastric balloon group (Treatment duration: **6 months**)versus medical treated group (Treatment duration: **20,1d**):

27P (IGB) 14fm/13m	Mean	SD	Min	Max	20P (MCT) 14fm/13m	Mean	SD	Min	Max	
Outcome BMI kg/m²	70,05	8,62	51,1	87,4	Outcome BMI kg/m²	66,17	5,95	55,5	78,4	n.s.
Outcome Weight kg	207,16	31,61	134	267	Outcome Weight kg	203,45	31,36	152	280	n.s.
BMI drop	7,34	3,17	3,2	12,3	BMI drop	7,12	3,46	3,6	16,2	n.s.
Weight loss kg	21,06	10,53	2	40	Weight loss kg	26,1	12,75	11	58	p>0,01 Cls 90%
EWL %	13,88	8,52	1,08	44,3	EWL %	13,87	5,27	6,4	25,1	n.s.

XXVII IFSO World Congress



Multiple linear regression (baseline weight, weight loss), Group 1 (medical treated group). Multiple linear regression (baseline weight, weight loss): Group 2 (control group – intragastric balloon).



XXVII IFSO World Congress



Aus der chirurgischen Klinik der Medizinischen Fakultät Mannheim (Direktor: Prof. Dr. med. Christoph Reißfelder)

"Validation of a novel score for urgent bariatric and metabolic surgery"

Inauguraldissertation zur Erlangung des medizinischen Doktorgrades der Medizinischen Fakultät Mannheim der Ruprecht-Karls-Universität zu Heidelberg

XXVII IFSO World Congress



TAKE HOME

There are clear criteria:

For non-ambulatory patients as a bridge to surgery, endoscopy, especially intragastric balloon therapy (nowadays alternatively endoscopic gastroplasty)

should be performed

provided there is no urgent need for immediate surgical rescue weight loss.
=> Thus defining the bariatric emergency patient

XXVII IFSO World Congress



THANK YOU FOR YOUR KIND ATTENTION

christine.stier@umm.de

XXVII IFSO World Congress

